Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) announced that 4,874,126 Series B warrants, representing approximately 38% of its total outstanding warrants, expired unexercised at 5:00 p.m. New York City time on May 19, 2026.
The warrants had a $0.95 exercise price. Their expiration issues no new shares, causes no dilution, reduces warrant overhang, and simplifies the capital structure.
Positive
- Expiration of 4,874,126 Series B warrants unexercised
- Elimination of approximately 38% of total outstanding warrants
- No new shares issued and no dilution to existing shareholders
- Reduced warrant overhang and simplified capital structure
Negative
- None.
News Market Reaction – COSM
In the May 21 session, COSM declined 10.20%, reflecting a significant negative market reaction. Argus tracked a peak move of +18.1% during that session. Argus tracked a trough of -3.1% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Crypto Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | EIB R&D financing | Positive | +1.2% | EIB advisory deal for up to €25M toward a €50M R&D program. |
| May 12 | S-1 withdrawal | Positive | +0.1% | Company withdraws unused Form S-1 for a public offering with no securities sold. |
| May 11 | Fort18 revenue outlook | Positive | -7.6% | Projects over $3.2M in incremental annual U.S. revenue from Fort18 within 12–18 months. |
| May 06 | Fort18 U.S. launch | Positive | -0.8% | Announces U.S. launch of Fort18 men’s stamina supplement with supportive clinical data. |
| Apr 30 | Cur18 revenue outlook | Positive | +2.5% | Projects over $2.5M in incremental annual U.S. revenue from Cur18 within 12–18 months. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent tagged news has been mostly positive, but price reactions have been mixed, with both aligned gains and notable selloffs on growth-oriented announcements.
Over the last month, Cosmos Health reported several financing, product, and capital-markets updates tagged under "crypto". These include an advisory agreement with the EIB for up to €25M under a €50M R&D program, withdrawal of a Form S‑1 public offering, and revenue projections of over $3.2M for Fort18™ and $2.5M for Cur18™. Product-launch and revenue‑projection news has sometimes coincided with negative price moves, while financing and registration decisions have seen modest positive reactions. Today’s warrant-expiration update fits into this ongoing capital-structure and growth narrative.
Key Terms
warrants financial
exercise price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
No dilution to existing shareholders
Reduction in total outstanding warrant overhang
Simplifies capital structure
CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its Series B warrants expired unexercised in accordance with their original terms at 5:00 p.m. New York City time on May 19, 2026.
The expired warrants carried an exercise price of
Their expiration eliminates this overhang with no new shares issued and no dilution to existing shareholders, while meaningfully simplifying the Company's capital structure going forward.
Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "The expiration of these warrants is a positive development for our shareholders. The elimination of 4.87 million warrant shares - representing almost
About Cosmos Health Inc.
Cosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire